Up up_老虎社区_美港股上老虎

2021-11-01

Up up

Moderna stock fell more than 6% in morning trading

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":843080039,"tweetId":"843080039","gmtCreate":1635782233036,"gmtModify":1635782233134,"author":{"id":3559700461523213,"idStr":"3559700461523213","authorId":3559700461523213,"authorIdStr":"3559700461523213","name":"Dont be weak","avatar":"https://static.tigerbbs.com/06b3e51be6a54224a834dd01de25f3cc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":12,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Up up</p></body></html>","htmlText":"<html><head></head><body><p>Up up</p></body></html>","text":"Up up","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/843080039","repostId":1107892081,"repostType":4,"repost":{"id":"1107892081","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635776429,"share":"https://www.laohu8.com/m/news/1107892081?lang=&edition=full","pubTime":"2021-11-01 22:20","market":"us","language":"en","title":"Moderna stock fell more than 6% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1107892081","media":"Tiger Newspress","summary":"Moderna stock fell more than 6% in morning trading as US approval on Moderna's Covid-19 vaccine for ","content":"<p>Moderna stock fell more than 6% in morning trading&nbsp;as&nbsp;US approval on Moderna's Covid-19 vaccine for teens delayed.</p>\n<p><img src=\"https://static.tigerbbs.com/3261879c71765f83062530060ce1876b\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>US biotech firm Moderna said Sunday (Oct 31) that American officials have delayed approving its Covid-19 vaccine for teenagers to allow more time to better assess the potential risk of developing myocarditis, or heart inflammation.</p>\n<p>The US Food and Drug Administration (FDA) on Friday \"informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination,\" the biotech company said Sunday in a statement.</p>\n<p>The evaluation on whether to recommend Moderna's vaccine for 12- to 17-year-olds could last until January 2022, the company said.</p>\n<p>Myocarditis and an associated risk, pericarditis (inflammation around the heart) have previously been linked to the Pfizer and Moderna Covid-19 vaccines themselves, particularly among adolescent boys and young men.</p>\n<p>But the risk is far higher after infection with Covid-19, according to a study published in August by the US Centers for Disease Control and Prevention (CDC).</p>\n<p>The CDC found that \"myocarditis following vaccination with mRNA vaccines has been rare and generally mild,\" Moderna said.</p>\n<p>Another mRNA Covid-19 vaccine, by Pfizer-BioNTech, on Friday received US authorization for children aged five to 11, in smaller doses than for adults.</p>\n<p>Moderna had previously said it was waiting for the FDA to decide on whether to approve its vaccine for adolescents under age 18 before seeking regulator approval for younger age groups.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock fell more than 6% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock fell more than 6% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-01 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna stock fell more than 6% in morning trading&nbsp;as&nbsp;US approval on Moderna's Covid-19 vaccine for teens delayed.</p>\n<p><img src=\"https://static.tigerbbs.com/3261879c71765f83062530060ce1876b\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>US biotech firm Moderna said Sunday (Oct 31) that American officials have delayed approving its Covid-19 vaccine for teenagers to allow more time to better assess the potential risk of developing myocarditis, or heart inflammation.</p>\n<p>The US Food and Drug Administration (FDA) on Friday \"informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination,\" the biotech company said Sunday in a statement.</p>\n<p>The evaluation on whether to recommend Moderna's vaccine for 12- to 17-year-olds could last until January 2022, the company said.</p>\n<p>Myocarditis and an associated risk, pericarditis (inflammation around the heart) have previously been linked to the Pfizer and Moderna Covid-19 vaccines themselves, particularly among adolescent boys and young men.</p>\n<p>But the risk is far higher after infection with Covid-19, according to a study published in August by the US Centers for Disease Control and Prevention (CDC).</p>\n<p>The CDC found that \"myocarditis following vaccination with mRNA vaccines has been rare and generally mild,\" Moderna said.</p>\n<p>Another mRNA Covid-19 vaccine, by Pfizer-BioNTech, on Friday received US authorization for children aged five to 11, in smaller doses than for adults.</p>\n<p>Moderna had previously said it was waiting for the FDA to decide on whether to approve its vaccine for adolescents under age 18 before seeking regulator approval for younger age groups.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107892081","content_text":"Moderna stock fell more than 6% in morning trading as US approval on Moderna's Covid-19 vaccine for teens delayed.\n\nUS biotech firm Moderna said Sunday (Oct 31) that American officials have delayed approving its Covid-19 vaccine for teenagers to allow more time to better assess the potential risk of developing myocarditis, or heart inflammation.\nThe US Food and Drug Administration (FDA) on Friday \"informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination,\" the biotech company said Sunday in a statement.\nThe evaluation on whether to recommend Moderna's vaccine for 12- to 17-year-olds could last until January 2022, the company said.\nMyocarditis and an associated risk, pericarditis (inflammation around the heart) have previously been linked to the Pfizer and Moderna Covid-19 vaccines themselves, particularly among adolescent boys and young men.\nBut the risk is far higher after infection with Covid-19, according to a study published in August by the US Centers for Disease Control and Prevention (CDC).\nThe CDC found that \"myocarditis following vaccination with mRNA vaccines has been rare and generally mild,\" Moderna said.\nAnother mRNA Covid-19 vaccine, by Pfizer-BioNTech, on Friday received US authorization for children aged five to 11, in smaller doses than for adults.\nModerna had previously said it was waiting for the FDA to decide on whether to approve its vaccine for adolescents under age 18 before seeking regulator approval for younger age groups.","news_type":1},"isVote":1,"tweetType":1,"viewCount":819,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/843080039"}